Clinical Trials on Intellectual Disabilities With Other Behavioral Symptoms in Russian Federation

Total 28 results

Histograft Co., Ltd.
Petrovsky National Research Center of Surgery

Recruiting

Comparative Study of Gene-Activated Bone Substitute "Histograft" for Lumbar and Cervical Spinal Fusion

Spinal Stenosis | Cervical Disc Disorder With Radiculopathy | Biomechanical Lesion, Unspecified | Lumbar and Other Intervertebral Disc Disorders With Radiculopathy

Russian Federation
Eli Lilly and Company

Completed

Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride Versus Placebo in Russian Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

Attention Deficit Disorder With Hyperactivity

Russian Federation
Russian Academy of Medical Sciences

Completed

Intranasal Inhalations of M2 Macrophage Soluble Factors in Children With Developmental Speech Disorders

Autism Spectrum Disorder | Language Delay | Language; Developmental Disorder, Expressive | Language; Developmental Disorder, Receptive | Attention Deficit-Hyperactivity Disorder | Speech Disorders in Children

Russian Federation
Moscow Psychiatric Hospital No. 1 Named after N...

Recruiting

Personalized Prospective Study Evaluation of the Efficacy and Safety of Noninvasive Neuromodulation of TMS in Subjects With Catatonia (RECATA)

Schizophrenia | Schizo Affective Disorder | Catatonia | Bipolar Affective Disorder

Russian Federation
AstraZeneca

Completed

Observational Study to Evaluate Bipolar Disorder Symptoms in Patients Presented With Schizophrenia or Depression

Schizophrenia | Schizoaffective Disorder | Recurrent Depression

Russian Federation
Materia Medica Holding

Completed

Efficacy and Safety of Tenoten for Children in the Treatment of Specific Developmental Disorders of Scholastic Skills in Children

Specific Developmental Disorders of Scholastic Skills

Russian Federation
AO GENERIUM

Completed

A Multi-cohort Study of the Tolerance, Safety, and Pharmacokinetics of GNR-055 in Healthy Volunteers

Metabolic Diseases | Mucopolysaccharidosis Type II

Russian Federation
Russian Academy of Medical Sciences

Completed

Intranasal Inhalations of Bioactive Factors Produced by M2 Macrophages in Patients With Organic Brain Syndrome

Neurocognitive Disorders | Brain Ischemia | Delirium, Dementia, Amnestic, Cognitive Disorders | Organic Brain Syndrome, Nonpsychotic | Mental Disorder, Organic | Nonpsychotic Organic Brain Syndrome | Organic Mental Disorder | Encephalopathy, Post-Traumatic, Chronic | Encephalopathy, Ischemic

Russian Federation
AO GENERIUM

Recruiting

A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type II

Metabolic Diseases | Mucopolysaccharidosis Type II

Russian Federation
Novartis Pharmaceuticals

Terminated

Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent

Major Depressive Disorder With Suicidal Ideation With Intent

Taiwan, Spain, Germany, Netherlands, Turkey, Mexico, United States, Malaysia, Poland, Canada, Japan, Russian Federation, Argentina, Brazil
Bioprojet

Active, not recruiting

Efficacy and Safety of Pitolisant in Pediatric Narcoleptic Patients With or Without Cataplexy, Double-blind Study Followed by a Prolonged Open-label Period

Narcolepsy Without Cataplexy | Narcolepsy With Cataplexy

France, Italy, Russian Federation, Finland, Netherlands
Materia Medica Holding

Completed

Clinical Trial of Efficacy and Safety of Prospecta in the Treatment of Attention Deficit/Hyperactivity Disorder in Children

Attention Deficit Hyperactivity Disorder

Russian Federation
Eli Lilly and Company

Completed

Study in Adolescents With Schizophrenia or Bipolar Disorder

Schizophrenia | Bipolar I Disorder

Puerto Rico, Russian Federation, United States, Poland
National Institute of Mental Health (NIMH)

Completed

Neuropsychological Evaluation of Psychiatric and Neurological Patients

Schizophrenia | Seizures | Head Injury | Anxiety Disorder | Mood Disorder

United States, France, Russian Federation
Janssen Research & Development, LLC

Completed

A Study of JNJ-61393215 in the Treatment of Depression

Major Depressive Disorder With Anxious Distress

United States, Moldova, Republic of, Russian Federation, Ukraine, United Kingdom
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Double-blind, Placebo-controlled Study of the Safety and Efficacy of Paliperidone Extended Release (ER) in the Treatment of Schizophrenia in Adolescent Patients

Schizophrenia

United States, India, Romania, Russian Federation, Ukraine
Sunovion

Completed

Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose (RESOLVE 1)

Major Depressive Disorder With Mixed Features

United States, Serbia, Ukraine, Russian Federation, United Kingdom
Eli Lilly and Company

Completed

Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine

Schizophrenia | Schizoaffective Disorders

United States, Puerto Rico, Mexico, Brazil, Israel, Korea, Republic of, Russian Federation
NeuroVia, Inc.

Withdrawn

Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Adrenoleukodystrophy

X-Linked Adrenoleukodystrophy

Australia, Argentina, United Kingdom, Colombia, Chile, France, Russian Federation, Ukraine
Johnson & Johnson Pharmaceutical Research & Development...
Janssen-Cilag International NV

Completed

A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia.

Schizophrenia

United States, Ukraine, Romania, South Africa, Taiwan, Korea, Republic of, Russian Federation, Costa Rica, Mexico
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features. (ATTAIN 267)

Adolescent Schizophrenia | Child or Adolescent Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features

India, United States, Bulgaria, Croatia, Hungary, Malaysia, Philippines, Poland, Romania, Russian Federation, Serbia, Taiwan, Ukraine
Merz Pharmaceuticals GmbH

Completed

Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability (SIPEXI)

Stroke | Cerebral Palsy | Intellectual Disability | Traumatic Brain Injury | Chronic Troublesome Sialorrhea

Georgia, Hungary, Poland, Russian Federation, Serbia, Ukraine
Targacept Inc.

Completed

Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia

Schizophrenia | Cognitive Dysfunction | Negative Symptoms

United States, Serbia, Ukraine, Russian Federation, Hungary, Romania
Alkermes, Inc.

Completed

Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder

Schizophrenia | Bipolar I Disorder | Schizophreniform Disorders

United States, Korea, Republic of, Russian Federation, Ukraine, Austria, Germany, Ireland, Israel, Italy, Poland, Spain, United Kingdom
Janssen-Cilag International NV

Completed

Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral Antipsychotics (PROSIPAL)

Schizophrenia

France, Ukraine, United Kingdom, Germany, Taiwan, Spain, Poland, Bulgaria, Romania, Russian Federation, South Africa, Greece, Israel, Korea, Republic of, Belgium, Estonia, Turkey, Czech Republic, Austria, Hungary, Lithuania, Slovakia and more
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation

Nervous System Diseases | Alzheimer's Disease | Mental Disorder | Agitation Associated With | Alzheimer's Type

Spain, United States, Germany, Croatia, Serbia, Russian Federation, Ukraine
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type

Nervous System Diseases | Alzheimer's Disease | Mental Disorder | Agitation Associated With | Alzheimer's Type

France, United States, Bulgaria, Slovenia, United Kingdom, Russian Federation, Ukraine, Finland, Canada
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo

Nervous System Diseases | Mental Disorder | Alzheimer's Type | Agitation Associated With Alzheimer's Disease

United States, Germany, France, Bulgaria, Spain, Slovenia, Croatia, Serbia, Russian Federation, Ukraine, Canada, United Kingdom

Clinical Trials on Intellectual Disabilities With Other Behavioral Symptoms in Russian Federation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Croatia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations